Neoadjuvant stereotactic ablative radiotherapy (SABR) for soft tissue sarcomas of the extremities

Imagem de Miniatura
Arquivos
art_LEITE_Neoadjuvant_stereotactic_ablative_radiotherapy_SABR_for_soft_tissue_2021.PDF (805.44 KB)
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
Citação
RADIOTHERAPY AND ONCOLOGY, v.161, p.222-229, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Soft tissue sarcomas (STS) comprise a diverse group of mesenchymal malignancies that require multidisciplinary care. Although surgery remains the primary form of treatment for those with localized disease, radiation therapy (RT) is often incorporated either in the neo-or adjuvant setting. Given the development of modern RT techniques and alternative dosing schedules, stereotactic ablative radiotherapy (SABR) has emerged as a promising technique. However, the current role of SABR in the treatment of STS of the extremities remains uncertain. Methods and Materials: This was a single-center, prospective, single-arm phase II trial. Patients with localized STS who were candidates for limb-preservation surgery were included. Experimental treatment consisted of SABR with 40 Gy in 5 fractions, administered on alternate days, followed by surgery after a minimum interval of 4 weeks. The primary outcome was the rate of wound complication. Secondary outcomes included 2-year local control (LC), metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS) rates (and other toxicities). Results: Twenty-five patients were enrolled between October 2015 and November 2019 and completed the treatment protocol. The median rate of histopathologic regression was 65% (range 0-100) and 20.8% of tumors presented pathologic complete response (pCR). Wound complications were observed in 7/25 patients (28%). Three patients underwent disarticulation by vascular occlusion after plastic reconstruction and one patient was amputated by grade 3 limb dysfunction. After a median follow up of 20.7 months, the 2-year estimated risk of local recurrence, distant metastasis and cause-specific death were 0%, 44.7% and 10.6% respectively. Conclusions: Neoadjuvant SABR appears to improve the pCR for patients with eSTS, with acceptable rate of wound complications. Nevertheless, this benefit should be weighed against the risk of late of vascular toxicity with SABR regimen since, even in a short median follow-up, a higher rate of amputation than expected was observed. A larger sample size with longer follow-up is necessary to conclude the overall safety of this strategy.
Palavras-chave
Soft tissue sarcoma, Sarcomas, Radiotherapy, SABR, Hypofractionation, Extremities
URI
https://observatorio.fm.usp.br/handle/OPI/41648
Referências
  1. Benedict SH, 2010, MED PHYS, V37, P4078, DOI 10.1118/1.3438081
  2. Canter RJ, 2010, ANN SURG ONCOL, V17, P2578, DOI 10.1245/s10434-010-1156-3
  3. Chow S, 2008, CHAPMAN HALL CRC BIO CHAPMAN HALL CRC BIO, V2nd, P86
  4. Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525
  5. Davis AM, 2005, RADIOTHER ONCOL, V75, P48, DOI 10.1016/j.radonc.2004.12.020
  6. Davis AM, 2002, J CLIN ONCOL, V20, P4472, DOI 10.1200/JCO.2002.03.084
  7. Eilber FC, 2001, J CLIN ONCOL, V19, P3203, DOI 10.1200/JCO.2001.19.13.3203
  8. Haas RLM, 2016, RADIOTHER ONCOL, V119, P14, DOI 10.1016/j.radonc.2015.12.002
  9. Kosela-Paterczyk H, 2014, EJSO-EUR J SURG ONC, V40, P1641, DOI 10.1016/j.ejso.2014.05.016
  10. Kubicek GJ, 2018, AM J CLIN ONCOL-CANC, V41, P86, DOI 10.1097/COC.0000000000000236
  11. Lazarev S, 2017, PRACT RADIAT ONCOL, V7, pE507, DOI 10.1016/j.prro.2017.04.010
  12. MacDermed DM, 2010, INT J RADIAT ONCOL, V76, P1147, DOI 10.1016/j.ijrobp.2009.03.015
  13. Mack LA, 2005, ANN SURG ONCOL, V12, P646, DOI 10.1245/ASO.2005.03.064
  14. Nivet A, 2019, CANCER RADIOTHER, V23, P161, DOI 10.1016/j.canrad.2018.05.009
  15. O'Sullivan B, 2002, LANCET, V359, P2235, DOI 10.1016/S0140-6736(02)09292-9
  16. O'Sullivan B, 2013, CANCER-AM CANCER SOC, V119, P1878, DOI 10.1002/cncr.27951
  17. Pennington JD, 2018, AM J CLIN ONCOL-CANC, V41, P1154, DOI 10.1097/COC.0000000000000443
  18. Pisters PWT, 2007, J CLIN ONCOL, V25, P1003, DOI 10.1200/JCO.2006.09.8525
  19. Pisters PWT, 1996, J CLIN ONCOL, V14, P859, DOI 10.1200/JCO.1996.14.3.859
  20. Potters L, 2010, INT J RADIAT ONCOL, V76, P326, DOI 10.1016/j.ijrobp.2009.09.042
  21. REITAN JB, 1980, BRIT J RADIOL, V53, P969, DOI 10.1259/0007-1285-53-634-969
  22. Ryan CW, 2008, CANCER-AM CANCER SOC, V112, P2432, DOI 10.1002/cncr.23478
  23. Shah D, 2012, ANTICANCER RES, V32, P3911
  24. Slump J, 2019, J PLAST RECONSTR AES, V72, P1449, DOI 10.1016/j.bjps.2019.05.041
  25. Soyfer V, 2013, BRIT J RADIOL, V86, DOI 10.1259/bjr.20130258
  26. Temple CLF, 2007, J SURG ONCOL, V95, P135, DOI 10.1002/jso.20629
  27. THAMES HD, 1986, INT J RADIAT ONCOL, V12, P687, DOI 10.1016/0360-3016(86)90081-7
  28. US Department of Health and Human Services, 2009, COMMON TERMINOLOGY C, P03
  29. Walshaw R, 2015, CLIN ONCOL-UK, V27, P544, DOI 10.1016/j.clon.2015.06.003
  30. Wang D, 2015, J CLIN ONCOL, V33, P2231, DOI 10.1200/JCO.2014.58.5828
  31. Wibmer C, 2010, ANN ONCOL, V21, P1106, DOI 10.1093/annonc/mdp415
  32. Yang JC, 1998, J CLIN ONCOL, V16, P197, DOI 10.1200/JCO.1998.16.1.197

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03